RNA-seq Analysis of PBMC in Patients With OPLL

Characteristics of Transcriptome Expression Profile of PBMCs in Patients With Ossification of the Posterior Longitudinal Ligament

In this study, we planned to identify transcriptome expression profiles (circRNAs, lncRNAs, and mRNAs) from peripheral blood mononuclear cells (PBMCs) of 30 patients with OPLL and 30 other non-OPLL patients by high-throughput sequencing.Sequence analysis was used to predict miRNAs that might bind circRNAs and lncRNAs.Through bioinformatics analysis, competitive endogenous RNAs (cerRNAs), as well as coexpression networks among circRNAs, lncRNAs, miRNAs, and mRNAs, were constructed to provide key molecules and signaling pathways associated with OPLL.

Study Overview

• Status: Recruiting
• Conditions: OPLL; Transcriptome; PBMCs; Bioinformatics

• Study Type: Observational
• Enrollment (Anticipated): 30

Contacts and Locations

• Study Contact: Name: Ning Jiang, M.D; Phone Number: +86 15653868023; Email: jiangn57@mail2.sysu.edu.cn

Study Locations

• China
  • Guangdong
    • Zhuhai, Guangdong, China
      • Recruiting
      • Facility
      • Contact: ning jiang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

A total of 30 peripheral blood samples were enrolled in this study, including 15 cases in the OPLL disease group and 15 cases in the non-OPLL control group.

Description

Inclusion Criteria:

1. Voluntarily participate in the clinical study and sign the informed consent;
2. All OPLL patients meet the diagnostic criteria set out in the JOA Clinical Practice Guidelines for Spinal Ligament Osification 2019;
3. Age ≥18, gender unlimited;
4. All non-OPLL patients and healthy volunteers have no serious diseases of the heart, lung, brain, liver, kidney and blood system, such as autoimmune diseases, tumors, psychosis, infectious diseases, etc., and have no bad habits or recent history of taking special drugs.

Exclusion Criteria:

1. Unable to sign the informed consent;
2. Patients who do not meet the inclusion criteria or diagnostic criteria;
3. <18 years old;
4. Women planning to become pregnant/lactating/pregnant;
5. Complicated with serious heart, lung, brain, liver, kidney, blood system diseases, such as autoimmune diseases, tumors, mental illness, infectious diseases, drug addiction and other bad addicts;Those who have recently taken special drugs;
6. Individuals who do not agree to donate peripheral blood or who are obviously uncomfortable with drawing blood.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
circRNA, lncRNA, mRNA	1 year

Collaborators and Investigators

• Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Study record dates

Study Major Dates

• Study Start (Actual): June 25, 2021
• Primary Completion (Anticipated): June 25, 2022
• Study Completion (Anticipated): June 30, 2022

Study Registration Dates

• First Submitted: July 2, 2021
• First Submitted That Met QC Criteria: July 7, 2021
• First Posted (Actual): July 15, 2021

Study Record Updates

• Last Update Posted (Actual): July 15, 2021
• Last Update Submitted That Met QC Criteria: July 7, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: ZDWY.CSYGJWK.003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No